FFFiona Fransen

Fiona Fransen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fiona Fransen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Joseph Meletiadis

    Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands

    3 shared publications
  • Johan W Mouton

    Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

    2 shared publications
  • Maria J B Melchers

    Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

    2 shared publications
  • Claudia C M Lagarde

    Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

    1 shared publication
  • Claudia M C Lagarde

    Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

    1 shared publication
  • Johan W. Mouton

    Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae

    by Fiona Fransen, Kelly Hermans, Maria J B Melchers, Claudia C M Lagarde, Joseph Meletiadis, Johan W Mouton

    The increase in antibiotic resistance in Gram-negative bacteria and the limited therapeutic options due to the shortage of new antibiotics have increased the interest of the ‘old’ antibiotic fosfomycin in the treatment of infections. However, there are contradictory reports on the pharmacodynamics of and emergence of resistance to fosfomycin. Time–kill assays were performed with 11 ESBL-positive and 3 ESBL-negative strains, exposing the bacteria to 2-fold static concentrations from 0.125× to 32× MIC. The sigmoid maximum effect (Emax) model was fitted to the time–kill curve data. Amplification of resistance over time was evaluated under various conditions of selective pressure by plating on 16× MIC plates. Fosfomycin was bactericidal for all strains within 8 h. Using the Emax model, no significant differences between strains were observed for the pharmacodynamic parameters. However, the large variation in Hill slope factors for Escherichia coli of 0.87 up to 4.02 indicates that the killing behaviour appears to be more time dependent for some strains but concentration dependent for others. In the fosfomycin-exposed cultures under low and high selective pressure (≥2× MIC) the median resistance proportions between the resistant and total population increased from ≤2 × 10−6 (T = 0 h) to 0.652–0.899 (T = 24 h). Resistance appeared stable after repeated subculturing. Killing behaviour of fosfomycin does not only differ between species but also within species and may have an impact on the design of optimal dosing regimens. Although fosfomycin was bactericidal against all strains (re)growth of resistant subpopulations occurred relatively fast. This may limit the use of fosfomycin as a single drug therapy.


  • Open Access

    Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections

    by Fiona Fransen, Maria J B Melchers, Claudia M C Lagarde, Joseph Meletiadis, Johan W Mouton

    Urinary tract infections are among the most common human infections. Due to the progressive increase in ESBL-producing bacteria and the unavailability of new antibiotics, re-evaluation of ‘old’ antibiotics is needed. However, the pharmacodynamics of nitrofurantoin under variable pH conditions are poorly understood. We determined the pharmacodynamic properties of nitrofurantoin at different pH levels using time–kill assays. Time–kill assays were performed at four pH levels (5.5, 6.5, 7.5 and 8.5), exposing the bacteria to 2-fold increasing concentrations from 0.125 to 32 times the MIC. Seven ESBL-positive and two ESBL-negative strains (MICs 8–32 mg/L) were used. The Δlog10 cfu/mL values at 6 and 24 h were plotted against each log10-transformed concentration and analysed with non-linear regression analysis using the sigmoid maximum effect model with variable slope. Geometric means normalized by the MIC of the EC50, stasis and 1 and 3 log10 cfu/mL kill were calculated. Minimum bactericidal effects differed significantly by species and pH level. At pH 5.5–6.5 bactericidal effects were observed at ≥ 0.5 × MIC for Escherichia coli and Enterobacter cloacae. At pH 8.5 only the two highest concentrations were considered bactericidal. Strong pH-dependent pharmacodynamic output parameters were observed in 6 h and especially 24 h modelling. At 24 h, pH 5.5–6.5 for E. coli and Klebsiella pneumoniae required significantly lower nitrofurantoin concentrations compared with pH 7.5 or 8.5. Although for E. cloacae similar strong decreasing trends were visible with decreasing pH, none of the tested pharmacodynamic parameters was significant. Nitrofurantoin bactericidal activity against Enterobacteriaceae significantly increases at lower pH levels. Bactericidal activity of nitrofurantoin may be overestimated or underestimated, which may have implications for therapy and the interpretation of clinical breakpoints.


  • Open Access

    Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections

    by Fiona Fransen, Maria J. B. Melchers, Joseph Meletiadis, Johan W. Mouton

    Although nitrofurantoin has been used for >60 years for the treatment of uncomplicated urinary tract infections, its pharmacodynamic properties are not fully explored. Use is increasing because of increasing resistance to other antimicrobials due to ESBLs. We tested nine ESBL+ and two ESBL− strains in time–kill assays. Bactericidal activity and regrowth were assessed for all species and concentrations. Early-phase pharmacodynamics was analysed with a sigmoidal Emax model and the maximal killing rate, slope and EC50/MIC ratio were determined for each species. A bactericidal effect was found at ≥2× MIC for Enterobacter cloacae after 4–8 h, for Klebsiella pneumoniae after 8–10 h and for Escherichia coli after 12–16 h. Overall, no killing was observed at low sub-MIC concentrations, whereas regrowth was found at 0.5–1× MIC after a short decline in cfu. The lowest maximal killing rates were observed for E. coli (0.21 ± 0.05 h−1), followed by K. pneumoniae (0.37 ± 0.09 h−1) and E. cloacae (0.87 ± 0.01 h−1). Surprisingly, the Hill slopes for these three species were significantly different (10.45 ± 9.37, 2.68 ± 0.64 and 1.01 ± 0.06, respectively), indicating a strong concentration-dependent early-phase antibacterial activity against E. cloacae. EC50/MIC ratios were significantly lower for E. coli (0.24 ± 0.08 mg/L) and K. pneumoniae (0.27 ± 0.03 mg/L) as compared with E. cloacae (0.77 ± 0.18 mg/L). Nitrofurantoin was bactericidal against all species, demonstrating an unusual differential pattern of activity with concentration-dependent-type killing behaviour against E. cloacae and time-dependent killing behaviour against E. coli, which may have significant consequences on species-dependent dosing regimens. The results also demonstrate that the pharmacodynamic properties of some drugs cannot be generalized within a family, here the Enterobacteriaceae.